Update on the treatment of hepatitis C genotypes 2-6
13 Oct 2014
The established measure of care for hepatitis C has consisted of pegylated interferon alpha combined with ribavirin. However, major side-effects and poor sustained virological responses are associated with this treatment. This recent review assessed the effects of the direct-acting antivirals upon hepatitis C genotypes 2-6 from publications from the past 18 months. Findings were the improvement of the impact of direct-acting antiviral treatments for genotypes 2-6, with marked lesser improvement for genotype 3.These treatments have raised sustained virological responses to maximum of 90 percent, revolutionizing treatment of all hepatitis C genotypes. Ongoing studies will improve treatment duration and develop interferon-free therapy options.